Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19450
Title: Predicting response after infliximab salvage in acute severe ulcerative colitis.
Authors: Choy, Matthew C;Seah, Dean;Gorelik, Alexandra;An, Yoon-Kyo;Chen, Cheng-Yu;Macrae, Finlay A;Sparrow, Miles P;Connell, William R;Moore, Gregory T;Radford-Smith, Graham;Van Langenberg, Daniel R;De Cruz, Peter
Affiliation: Department of Gastroenterology, Eastern Health, Melbourne, Australia
Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, Melbourne, Australia
Department of Gastroenterology, Alfred Health, Melbourne, Australia
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Department of Gastroenterology, Monash Health, Melbourne, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Institute for Health and Aging, Australian Catholic University, Melbourne, Australia
Department of Medicine (RMH), University of Melbourne, Melbourne, Australia
Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Australia
Issue Date: Jul-2018
EDate: 2018-02-27
Citation: Journal of Gastroenterology and Hepatology 2018; 33(7): 1347-1352
Abstract: Acute severe ulcerative colitis (ASUC) is a medical emergency requiring prompt therapeutic intervention. Although infliximab has been used as salvage therapy for over 15 years, clinical predictors of treatment success are lacking. We performed a retrospective analysis to identify factors that predict colectomy and may guide dose intensification. Fifty-four hospitalized patients received infliximab for ASUC at seven Australian centers (April 2014-May 2015). Follow-up was over 12 months. The data were primarily analyzed for predictors of colectomy. Accelerated (AI) versus standard (SI) infliximab induction strategies were also compared. Of 54 patients identified, the overall colectomy rate was 15.38% (8/52) at 3 months and 26.92% (14/52) at 12 months. Two patients were lost to follow-up. There was a numerically higher colectomy rate in those treated with AI compared with SI (P = 0.3); however, those treated with AI had more severe biochemical disease. A C-reactive protein (CRP)/albumin ratio cut-off of 0.37 post-commencement of infliximab and before discharge was a significant predictor of colectomy with an area under receiver operating curve of 0.73. Pretreatment CRP and albumin levels were not predictive of colectomy. A Mayo Endoscopic Score of 2 had a 94% PPV for avoidance of colectomy following infliximab salvage. The baseline Mayo Endoscopic Score and the CRP/albumin ratio following infliximab salvage are significant predictors of treatment response for ASUC and identify patients at high risk of colectomy. Whether this risk can be mitigated using infliximab dose intensification requires prospective evaluation before the CRP/albumin ratio can be integrated into ASUC management algorithms.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19450
DOI: 10.1111/jgh.14072
ORCID: 0000-0001-5206-0097
0000-0003-3662-6307
PubMed URL: 29266456
Type: Journal Article
Subjects: colectomy
infliximab
ulcerative colitis
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.